<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839890</url>
  </required_header>
  <id_info>
    <org_study_id>PEBSI-01</org_study_id>
    <nct_id>NCT01839890</nct_id>
  </id_info>
  <brief_title>Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction</brief_title>
  <acronym>PEBSI-01</acronym>
  <official_title>Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction After Bare Metal Stent Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francisco Javier Goicolea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective is the evaluation of safety and efficacy at 9 months of combination treatment
      of bare metal Stent plus Paclitaxel Eluting Balloon vs bare metal stent (conventional
      treatment) in patients with acute myocardial infarction with systolic time elevation of less
      than 12 hours of evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, randomized, open study

      After the permeabilization of the clinical event responsible artery and the insertion of a
      bare metal stent, patients will be randomized in a 1:1 ratio to one of the following
      treatment groups:

      Group 1: post-dilatation with a paclitaxel eluting balloon (Pantera Lux ®) Group 2: no
      post-dilatation Patients (or their legal representative) must sign the consent before
      randomization.

      After surgery, patients will be treated with dual antiplatelet therapy (aspirin plus
      clopidogrel) for at least one month to group 2 patients; and at least 3 months in those who
      are also treated with the paclitaxel eluting balloon (group 1). Aspirin is prescribed
      indefinitely according to the usual practice in these patients.

      Patients will be monitored 30 days after surgery, at 6 and 12 months, and the ninth month (in
      which patient will receive an angiographic control).

      The primary efficacy endpoint is late lumen loss (PLT) comparing it value during surgery and
      control angiography at 9 months

      This study will involve patients over 18 years olds with systolic time elevation myocardial
      infarction, or new left bundle branch block or posterior AMI (ECG) that occur within 12 hours
      of onset of symptoms to treatment by primary angioplasty.

      They include a total of 220 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Luminal Loss</measure>
    <time_frame>1 year</time_frame>
    <description>Loss measured in millimeters of late luminal space in vessels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy: angiography restenosis, minimal luminal diameter, ischemia directed target vessel revascularization (TVR), MACE (death, infarction, TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>Safety: MACE/ month, at 6 months and 12 months (death, re-infarction, acute cardiovascular disease, hemorrhagy and/or stent thrombosis).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bare metal Stent plus Paclitaxel Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare metal Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Bare Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal Stent plus Paclitaxel Balloon</intervention_name>
    <description>After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio</description>
    <arm_group_label>Bare metal Stent plus Paclitaxel Balloon</arm_group_label>
    <other_name>Balloon PANTERA LUX (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal Stent</intervention_name>
    <description>After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio</description>
    <arm_group_label>Bare metal Stent</arm_group_label>
    <other_name>PROKINETIC ENERGY (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged less than 18 years.

          -  Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of
             symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous
             leads), new left bundle branch block, or true posterior infarction.

          -  Patients candidates for primary angioplasty as medical criteria

          -  Written informed consent according to International Conference on Harmonization /
             Guide Clinical Practice and local legislation, obtained before any study procedure.

          -  Diameter vascular coronary artery to treat between 2 mm and 4 mm.

          -  Patients with 90-100% stenosis.

        Exclusion Criteria:

          -  Patients who refuse to participate in the study

          -  Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than
             30 minutes or need for vasopressors or intra-aortic balloon counterpulsation)

          -  Concomitant diseases associated with a life expectancy of less than one year

          -  Angiographic variables:

               -  Trunk unprotected

               -  Branching (side branch greater than 2.5 mm)

               -  Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to
                  stent

               -  If more than one stent to treat a single segment (overlapping stents).

               -  Patient candidate for surgical revascularization within 30 days

               -  Stenosis of greater than 30 mm in length (corresponding with the ball longer
                  available)

               -  Reference vessel diameter less than 2.5 mm and greater than 4 mm (larger ball)

               -  More severe stenosis in the same artery in which is expected to be addressed in
                  the next 9 months

          -  Women at childbearing age, where there is the possibility of pregnancy during the
             first year of follow-up, or nursing.

          -  Any clinical condition, which in the opinion of the investigator, is considered
             clinically significant as to participate in the study.

          -  Subjects who are participating in any study drug or medical.

          -  Individuals who show inability to follow instructions or help during the course of the
             study.

          -  Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral
             circulatory disorders, restricting the use of treatments platelet aggregation
             inhibitors and anticoagulants.

          -  Patients with an ejection fraction &lt;30% (if known).

          -  Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally
             related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration.

          -  Severe allergy to contrast media.

          -  Coronary artery spasm in the absence of significant stenosis.

          -  Cases in which is indicated bypass surgery within 30 days after infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J. Goicolea, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Puerta de Hierro. Majadahonda. Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complexo Hospitalario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usanso</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Regional Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Valle de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular</investigator_affiliation>
    <investigator_full_name>Francisco Javier Goicolea</investigator_full_name>
    <investigator_title>Dr. Fco. Javier Goicolea</investigator_title>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>stent</keyword>
  <keyword>Acute infarction</keyword>
  <keyword>Systolic time elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

